1NARABAYASHI M, SAIJO Y, TAKENOSHITA S,et al. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open- label trial [J].Jpn J Clin Oncol, 2008,38(4) : 296-304.
2OERTEL B G, KETYNER M, SCHOLICH K,et al. A common hu- man micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory informa- tion of pain[ J]. J Biol Chem,2009,284(10) :6530-6535.
3CAI W M. Pharmacogenomic and individualized medicin [ J].中国药学杂志,2007,42(24):1841-1844.
4KATHIRAMALAINATHAN K,KAPLAN H L, ROMACH M K,et al. Inhibition of cytochrome 17450 2D6 modified codeine abuse li- ability [ J ]. J Clin Psychopharmacol, 2000,20 ( 4 ) : 435-444.
5FERNANDES L, KILICARSLAN T, KAPLAN H, et al. Treatment of codeine dependence with inhibitors of cytochrome P450 2136 [ J ]. J Clin Psychopharmacol, 2002,22 ( 3 ) :326-329.
6STAMER U M, LEHNEN K, HOTHKER F, et al. Impact of C YP2D6 genotype on postoperative tramadol analgesia [ J ]. Pain, 2003,105 (1-2) :231-238.
7STAMER U M, MUSSHOFF F, KOBILAY M,et al. Concentra-tions of tramadol and O-desmethyhramadol enantiomers in differ- ent CYP2D6 genotypes [ J ]. Clin Pharmacol Ther, 2007, 82 (1) :41-47.
8DI PATTI F, FANELLI D, PEDERSEN R S, et al. Modelling the pharmaeokinetics of tramadol: On the difference between CYP2D6 extensive and poor metabolizers [ J ]. J Theor Bid, 2008,254 ( 3 ) : 568-574.
9GARCIA-QUETGLAS E,AZANZA J R,SADABA B, et al. Phar- maeokineties of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype [ J ]. Pharmacol Res, 2007,55 (2) :122-130.
10KLESS T M, SHEFFELS P, DALE O, et al. Metabolism of alfen- tanil by cytochrome p4503 a (cyp3a) enzymes [ J ]. Drug Metab Dispos ,2005,33 ( 3 ) : 303-311.
5Mattoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy [ J ]. Support Care Cancer,2005,13(11) :888.
6King SJ, Reid C, Forbes K, et al. A systematic review of oxycodone in the management of cancer pain [ J ]. Palliat Med July, 2011,25 (5) : 454.
7National Comprehensive Cancer Network. Clinical prac- tice guideline in oncology: adult cancer pain[EB/OL]. (2016-03-17)[2016-04-09]. https ://www.nccn.org/store/ login/login.aspx?ReturnURL=https://www.nccn.org/profe- ssionals/physician_gls/pdf/pain.pdf.
8Hwang IC, Park JY, Myung SK, et al. OPRM1 A118G gene variant and postoperative opioid requirement: a sys- tematic review and meta-analysis[J].Anesthesiology, 2014, 121(4):825.
9Ren ZY, Xu XQ, Bao YP, et al. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and me- m-analysis[J]. Pain Physician, 2015,18(2) : 131.
10Zhang F, Liao Q, Li L, et al. The correlation between post-operative fentanyl requirements and μ-opioid recep- tor gene A118G polymorphism in patients undergoing rad- ical gastrectomy[J]. Exp TherMed, 2013,5(4), 1 147.
